Results 231 to 240 of about 18,306,499 (332)

Patient healthcare spending after the No Surprises Act: quasi-experimental difference-in-differences study.

BMJ
Liu M, Kadakia KT, Mein SA, Wadhera RK.
europepmc   +1 more source

Evaluating the impact of a structured medication optimisation review on prescribing patterns and bleeding risk among patients prescribed direct oral anticoagulants (DOACs): a difference-in-differences study. [PDF]

BMJ Open Qual
Camacho EM, Butters O, Daras K, Downing J, Bateman J, Lynch S, Buchan IE, Barr B.   +7 more
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Insurance coverage and employment after Medicaid expansion with work requirements: quasi-experimental difference-in-differences study.

BMJ
Johnson DY, Mein SA, Marinacci LX, Liu M, Wadhera RK.   +4 more
europepmc   +1 more source

Annual cases of colon cancer by age group after Medicaid expansion in the USA in 2014: a difference-in-differences study. [PDF]

BMJ Open
Asiimwe E, May F, Bendavid E.
europepmc   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Impact of domestic violence legislation on reported intimate partner violence: a difference-in-differences analysis across 16 countries. [PDF]

SSM Popul Health
Richardson RA, Raj A, Downs K, Bergenfeld I, Wiltshire C, Dimitrova A, Benmarhnia T.   +6 more
europepmc   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Changes in hospital financial performance and quality of care after real estate investment trust acquisition: quasi-experimental difference-in-differences study.

BMJ
Bruch JD, Ramesh T, Yu EB, Zheng J, Phelan J, Orav EJ, Tsai TC.   +6 more
europepmc   +1 more source

Federated difference-in-differences with multiple time periods in DataSHIELD. [PDF]

iScience
Huth M, Garavito CA, Seep L, Cirera L, Saúte F, Sicuri E, Hasenauer J.   +6 more
europepmc   +1 more source